Eosinophilic cellulitis (Wells' syndrome) as a cutaneous reaction to the administration of adalimumab.
Boura
P
P
Sarantopoulos
A
A
Lefaki
I
I
Skendros
P
P
Papadopoulos
P
P
D000068879:Adalimumab; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy; D002481:Cellulitis / Q000139:chemically induced*; D004802:Eosinophilia / Q000139:chemically induced*; D005260:Female; D006801:Humans; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab